Detecting Early Stage Diabetic Retinopathy

检测早期糖尿病视网膜病变

• 批准号: 9108877
• 负责人: Machelle T. Pardue
• 金额: --
• 依托单位: VETERANS HEALTH ADMINISTRATION
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-01 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9108877
• 关键词: Adult; Age; Age-Years; Animal Model; Animals; Antioxidants; Apoptotic; Appearance; Blindness; Blood Circulation; Blood Vessels; Blood capillaries; Clinical; Contrast Media; Data; Defect; Detection; Devices; Diabetes Mellitus; Diabetic Retinopathy; Diagnosis; Diagnostic; Disease Progression; Dropout; Drops; Early Diagnosis; Early Intervention; Early identification; Early treatment; Evaluation; Extravasation; Family; Fluorescein; Functional disorder; Future; Goals; Human; Hyperglycemia; Hypoxia; Image; Immunohistochemistry; Incidence; Inflammatory Response; Insulin; Intervention; Lesion; Measures; Neuronal Dysfunction; Neurons; Non-Invasive Cancer Detection; Oxidative Stress; Pathogenesis; Pathologic; Pathology; Patients; Pericytes; Photography; Play; Prevalence; Reactive Oxygen Species; Receiver Operating Characteristics; Research Design; Retina; Retinal; Retinal Degeneration; Retinal Diseases; Rodent Model; Role; Sensitivity and Specificity; Staging; Stimulus; Streptozocin; System; Telemedicine; Testing; Therapeutic; Translations; Vascular Diseases; Vision; Visual; Visual Acuity; Work; age related; base; capillary; clinical Diagnosis; clinically significant; design; diabetic; diabetic rat; discrete time; early onset; human subject; improved; in vivo; inflammatory marker; instrument; macular edema; neovascularization; novel; pre-clinical; prevent; research study; response; retina blood vessel structure; retinal ischemia; retinal neuron; retinal rods; screening; tauroursodeoxycholic acid; therapeutic target; tool; type I and type II diabetes

DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) is the leading cause of blindness in adults 20 to 74 years of age. Detecting early stage retinopathy prior to the onset of clinical findings would greatly impact the management and treatment of DR. The goal of this proposal is to develop new tests that could serve as screening or diagnostic tools for early DR. We have identified several tests that show dysfunctional changes prior to the onset of clinically-significant vascular lesions induced by diabetes. These tests need to be further evaluated to establish 1) the relationship between theses functional changes in retinal neurons and late stage vascular lesions that cause vision loss; 2) the temporal progression of the retinal vascular and neuronal changes to determine predictability of the test for vision loss; 3) the sensitivity and specificity of the tests to posiively detect retinopathy while identifying normal retinas and 4) if identification of early stage DR provides an earlier window for intervention. The study design also provides a unique opportunity to determine the pathophysiological mechanisms underlying early stage DR. In this proposal, we will pursue the following aims: Aim 1: Identify non-invasive objective measures to diagnose preclinical DR. We will determine if the appearance of reactive oxygen species (ROS) occurs simultaneously with retinal and visual dysfunction in early stage DR and if this correlates with late stage pericyte dropout and acellular capillaries. Receiver operating characteristic (ROC) analysis will be used to determine detection threshold for each test. Aim 2: Elucidate the mechanisms underlying early stage DR by evaluation the timecourse of oxidative stress and neuronal and vascular dysfunction. To investigate the underlying mechanisms of early DR, we will use functional data and carefully chosen ex vivo markers to determine if early-stage vascular changes in DR induce hypoxia which leads to neuronal changes or if early-stage neuronal changes produce an inflammatory response which initiates vascular dysfunction. Aim 3. Determine if treating early stage diabetic retinopathy prevents the progression of DR. We will investigate three therapeutic approaches: a general anti-oxidant (AREDS anti-oxidant supplement), a dual acting anti-oxidant/anti-apoptotic agent (tauroursodeoxycholic acid (TUDCA)) and insulin. Each approach will be applied either at the onset of the earliest neuronal dysfunction as detected by our non-invasive detection tools or at clinical onset of retinopathy as indicated by pericyte dropout and fluorescein leakage. This aim will determine if early intervention prevents late stage vascular changes. This proposal will establish detection tools of early DR and determine the efficacy of early intervention to prevent disease progression. These studies use rodent models of both Type I and Type II diabetes to establish utility and potential mechanistic connections that are clinically inaccessible. We have crafted detection tools by combining clinically available devices (ERG, SLO, retinal photography) with novel stimuli, conditions, or contrast agents to facilitate rapid clinical translation. Detecting early sage retinopathy prior to the onset of clinical findings and vision loss would greatly improve the management and treatment of DR. The results of these studies will establish a set of objective measures for detection of early stage DR that will be tested in human subjects in future studies.

描述（由申请人提供）： 糖尿病视网膜病变（DR）是20至74岁成人失明的主要原因。在临床发现之前检测早期视网膜病变将极大地影响DR的管理和治疗。本提案的目标是开发新的测试，可以作为早期DR的筛查或诊断工具。我们已经确定了几个测试，显示功能障碍的变化之前，由糖尿病引起的临床显著的血管病变。这些测试需要进一步评估，以建立1）视网膜神经元的这些功能变化与导致视力丧失的晚期血管病变之间的关系; 2）视网膜血管和神经元变化的时间进展，以确定视力丧失测试的可预测性; 3）在识别正常视网膜的同时阳性检测视网膜病变的测试的灵敏度和特异性，以及4）早期DR的识别是否提供了更早的干预窗口。本研究设计还提供了一个独特的机会来确定早期DR的病理生理机制。在本提案中，我们将追求以下目标：目标1：确定诊断临床前DR的非侵入性客观措施。我们将确定是否出现活性氧（ROS）在早期DR中与视网膜和视觉功能障碍同时发生，如果这与晚期周细胞脱落和无细胞毛细血管相关。将使用受试者工作特征（ROC）分析确定每项检测的检测阈值。 目的2：通过评价氧化应激与神经和血管功能障碍的时程，阐明早期DR的机制。为了研究早期DR的潜在机制，我们将使用功能数据和精心选择的离体标记物来确定DR中的早期血管变化是否诱导导致神经元变化的缺氧，或者早期神经元变化是否产生引发血管功能障碍的炎症反应。 目标3。我们将研究三种治疗方法：一般抗氧化剂（AREDS抗氧化剂补充剂），双重作用的抗氧化剂/抗凋亡剂（牛磺熊去氧胆酸（TUDCA））和胰岛素。每种方法将在我们的非侵入性检测工具检测到的最早神经元功能障碍发作时或在由周细胞脱落和荧光素渗漏指示的视网膜病变临床发作时应用。这一目标将确定早期干预是否能预防晚期血管变化。 该提案将建立早期DR的检测工具，并确定早期干预预防疾病进展的有效性。这些研究使用I型和II型糖尿病的啮齿动物模型来建立临床上无法获得的实用性和潜在的机制联系。我们通过将临床可用的设备（ERG，SLO，视网膜摄影）与新的刺激，条件或造影剂相结合来制作检测工具，以促进快速的临床翻译。在临床发现和视力丧失发生之前检测早期鼠尾草视网膜病变将大大改善DR的管理和治疗。这些研究的结果将建立一套用于检测早期DR的客观措施，这些措施将在未来的研究中在人类受试者中进行测试。